Drug Profile

DF 006

Alternative Names: DF-006

Latest Information Update: 28 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Drug Farm
Class Antineoplastics; Antivirals; Hepatoprotectants; Small molecules
Mechanism of Action ALPK1 protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Hepatitis B; Liver cancer

Most Recent Events

28 Jun 2025 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in South Korea (PO)
27 May 2025 Amoytop Biotech and Drug Farm collaborates for the development DF-006 in hepatitis B and Liver cancer
15 Nov 2024 Pharmacodynamics data from a phase I trial in Hepatitis B presented at the The Liver Meeting 2024: 75^th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com